Income taxes (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
|---|
| Income taxes |
|
| Schedule of reconciliation of income taxes at statutory rates with the reported taxes |
| | | | | | | | | 2025 | | 2024 | | | $ | | $ | | | (Restated – see Note 4) | | (Restated – see Note 4) | Loss for the year | | | (44,214,333) | | | (23,664,711) | Expected income tax (recovery) | | | (11,938,000) | | | (6,389,000) | Change in statutory tax, foreign tax, foreign exchange rates | | | 107,000 | | | (129,000) | Permanent differences | | | 6,612,000 | | | 1,501,000 | Share issue costs and financing fee | | | (241,000) | | | (440,000) | Change in statutory tax rate | | | (294,000) | | | 25,000 | Change in unrecognized deductible temporary differences | | | 5,754,000 | | | 5,432,000 | Total income tax expense (recovery) | | | — | | | — | | | | | | | | Current income tax | | $ | — | | $ | — | Deferred tax recovery | | $ | — | | $ | — |
|
| Schedule of deferred income tax |
| | | | | | | 2025 | | 2024 | | | $ | | $ | | | (Restated – see Note 4) | | (Restated – see Note 4) | Equipment and license | | 759,000 | | 624,000 | R&D under Section 174 | | 1,508,000 | | 1,186,000 | US R&D tax credit | | 574,000 | | — | Share issue costs and financing fee | | 518,000 | | 572,000 | Foreign exchange | | (13,000) | | (10,000) | Unpaid accrued bonus and vacation | | 63,000 | | — | Scientific research and experimental development expenditures | | 3,609,000 | | 3,278,000 | Non-capital losses available for future periods | | 20,348,000 | | 15,977,000 | | | 27,366,000 | | 21,627,000 | Unrecognized deferred tax asset | | (27,366,000) | | (21,627,000) | Net deferred tax assets | | — | | — |
|
| Schedule of components of the Company's temporary differences, unused tax credits and unused tax losses |
| | | | | | | | | | | 2025 | | Expiry | | 2024 | | Expiry | | | $ | | | | $ | | | Equipment and license | | 2,814,000 | | None | | 2,310,000 | | None | R&D under Section 174 | | 7,179,000 | | None | | 5,649,000 | | None | US R&D tax credit | | 574,000 | | 2044-2045 | | — | | None | Share issue costs and financing fee | | 1,919,000 | | 2046-2049 | | 2,117,000 | | 2045-2048 | SRED pool | | 7,319,000 | | None | | 6,726,000 | | None | Federal SRED ITC | | 1,090,000 | | 2039-2045 | | 992,000 | | 2039-2044 | BC SRED ITC | | 543,000 | | 2029-2035 | | 470,000 | | 2029-2034 | Non-capital losses available for future periods | | 77,813,000 | | See below | | 60,713,000 | | See below | Canada | | 66,240,000 | | 2036-2045 | | 52,621,000 | | 2036-2044 | USA | | 10,658,000 | | None | | 7,430,000 | | None | Australia | | 915,000 | | None | | 662,000 | | None |
|